Zevra Therapeutics, Inc.

NASDAQ:ZVRA

Biotechnology

Healthcare
$9.28 +2.44%

+$0.31 today

Market cap
$552.20M
Beta
0.89
P/E (TTM)
6.1
EPS (TTM)
$2.13
52W Low $7.16High $14.27

Volume 0.62M

Average 1.43M

Income Statement

Follow revenue through to earnings.

Revenue

$106.47M

FY 2025 · Annual

+350.9% YoY

Operating Income

-$4.23M

FY 2025 · Annual

Net Income

$83.23M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue28.65M10.16M27.46M23.61M106.47M
Cost of Revenue2.06M222K2.95M7.42M16.48M
Gross Profit26.59M9.94M24.52M16.2M89.99M
Gross Margin92.8%97.8%89.3%68.6%84.5%
Research & Development10.16M19.8M39.81M42.1M12.74M
Selling, General & Admin8.7M15.04M35.09M54.87M77.62M
Operating Expenses18.86M52.5M74.12M103.2M94.22M
Depreciation & Amortization257K944K1.01M6.39M4.05M
EBITDA(7.89M)(25.53M)(43.54M)(76.4M)98.71M
EBITDA Margin-27.5%-251.2%-158.6%-323.6%92.7%
Operating Income7.73M(42.57M)(49.6M)(87M)(4.23M)
Operating Margin27.0%-418.9%-180.6%-368.5%-4.0%
Interest Income261K1.51M4.54M2.18M6.95M
Interest Expense376K335K1.5M7.35M7.98M
Other Income / Expenses(16.25M)15.76M3.56M(3.14M)90.91M
Income Before Tax(8.52M)(26.81M)(46.05M)(90.14M)86.68M
Pre-Tax Margin-29.7%-263.8%-167.7%-381.8%81.4%
Income Tax Expense34K(33K)015.37M3.45M
Net Income(8.56M)(26.77M)(46.05M)(105.51M)83.23M
Net Margin-29.9%-263.5%-167.7%-446.9%78.2%
EPS (Basic)(2.11)(0.78)(1.30)(2.28)1.40
EPS (Diluted)(2.11)(0.78)(1.30)(2.28)1.35
Weighted Avg Shares29.77M34.49M35.45M46.25M55.31M
Weighted Avg Shares (Diluted)29.77M34.49M35.45M46.25M57.26M

ZVRA Earnings Waterfall · TTM

NASDAQ:ZVRA · Revenue to Net Income

Key Ratios

EPS$2.15
Gross Margin83.9%
Net Margin106.7%
P/E Ratio-57.3
P/S Ratio17.2

Analysis

$122.3M of revenue converted into $124.2M of net income for the selected period. Gross margin is 83.9% and net margin is 106.7%, showing how much revenue survives after costs and taxes. EPS is $2.15, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 5, 2026
8-KCurrent reportNov 3, 2026
10-QQuarterly reportNov 3, 2026
4Statement of changes in beneficial ownershipOct 13, 2026
4Statement of changes in beneficial ownershipAug 17, 2026

How much revenue does ZVRA generate?

Zevra Therapeutics, Inc. (ZVRA) reported $106.47M of revenue in fiscal 2025.

Is ZVRA profitable?

Zevra Therapeutics, Inc. (ZVRA) reported $83.23M of net income, with a net margin of 78.2%.